Medical technology company HeartBeam has secured two new patents from the US Patent and Trademark Office on its core vector electrocardiography (VECG) technology.

HeartBeam’s VECG technology gathers 3D signals of the heart, transforming them into a 12-lead ECG.

The first patent is ‘Mobile three-lead cardiac monitoring device and method for automated diagnostics’.

It encompasses both apparatuses and methodologies designed to facilitate the comparison of cardiac signals over time, specifically for the automated or assisted detection of heart attacks, known as acute myocardial infarction.

With this patent, HeartBeam provides an approach wherein each patient receives a personalised baseline ECG, aiding physicians in obtaining deeper insights into the patient's cardiac well-being.

The apparatus for generating an electrocardiogram patent focuses on HeartBeam's wrist-based ECG system, marking the second patent related to the company's watch concept.

HeartBeam's watch device is designed to combine continuous ECG monitoring with the ability to capture a high-sensitivity 12-lead ECG.

HeartBeam CEO and founder Branislav Vajdic said: “HeartBeam’s core VECG technology is designed to be used with portable, patient-friendly devices such as a credit-card-sized system, an extended wear patch, or watch to enable physicians to monitor patients and identify cardiac health trends outside of a medical facility.

“These new patents reinforce our strategic vision, which is founded on developing and protecting our novel VECG technology and product pipeline as we work to transform how cardiac care is delivered in the future.”

The company now has a total of 14 granted and allowed US patents alongside four international patents for its VECG technology.

In December 2023, HeartBeam announced significant developments in the artificial intelligence applied to its VECG technology.